- Home
- XNCR
XNCR
Xencor Inc.
as 11-21-2024 12:42pm EST
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 1.5B | IPO Year: | 2013 |
| Target Price: | $35.50 | AVG Volume (30 days): | 553.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.31 - $26.84 | Next Earning Date: | 11-06-2024 |
| Revenue: | $85,164,000 | Revenue Growth: | -41.37% |
| Revenue Growth (this year): | -60.31% | Revenue Growth (next year): | 86.53% |
Stock Insider Trading Activity of Xencor Inc. (XNCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Nov 11 '24 | Sell | $23.48 | 68,684 | $1,612,638.50 | 200,104 | |
| GUSTAFSON KURT A | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 9,490 | |
| GORMAN KEVIN CHARLES | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,654 | $54,884.72 | 8,392 | |
| Feigal Ellen | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 8,490 | |
| Montgomery Alan Bruce | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 1,853 | $38,320.04 | 9,140 | |
| ROSA-BJORKESON DAGMAR | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 8,490 | |
| RANIERI RICHARD J | XNCR | Director | Sep 27 '24 | Sell | $20.68 | 2,503 | $51,762.04 | 8,490 |
Latest Xencor Inc. News
XNCR Breaking Stock News: Dive into XNCR Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Top Premarket Gainers
Zacks
3 days ago
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
Zacks
7 days ago
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
MT Newswires
8 days ago
Xencor Insider Sold Shares Worth $1,612,639, According to a Recent SEC Filing
Argus Research
9 days ago
XNCR: Raising target price to $25.00
Simply Wall St.
9 days ago
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%
Zacks
15 days ago
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
15 days ago
Xencor: Q3 Earnings Snapshot
Compare XNCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XNCR Xencor Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.